Brief: Evaxion Receives FDA Approval To Proceed With Clinical Phase 2b Study For EVX-01

Evaxion A/S

03/01/2023 13:06

Jan 3 (Reuters) - Evaxion Biotech A/S  EVAX.O :
    * EVAXION RECEIVES APPROVAL FROM FDA TO PROCEED WITH THE
CLINICAL
PHASE 2B STUDY FOR EVX-01
    * EVAXION BIOTECH A/S - ANTICIPATES A RESPONSE TO FAST TRACK
DESIGNATION SUBMISSION IN Q1 OF 2023
    * EVAXION BIOTECH A/S - PHASE 2B STUDY WILL BE CONDUCTED AT
CLINICAL SITES ACROSS UNITED STATES, EUROPE, AND AUSTRALIA
    * EVAXION BIOTECH A/S - COMPANY ANTICIPATES A RESPONSE TO
FAST
TRACK DESIGNATION SUBMISSION IN Q1 OF 2023

Source text for Eikon:  ID:nGNX85MYSr 
Further company coverage:  EVAX.O 
 ((Reuters.Briefs@thomsonreuters.com;))